Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-053318
Filing Date
2025-04-11
Accepted
2025-04-11 16:41:02
Documents
1
Period of Report
2025-04-10

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3809
  Complete submission text file 0000950170-25-053318.txt   5421
Mailing Address C/O ALEXION PHARMACEUTICALS, INC 352 KNOTTER DRIVE CHESHIRE CT 06410
Business Address
Hallal David (Reporting) CIK: 0001457477 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39409 | Film No.: 25832723

Mailing Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301
Business Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 650-249-2727
Kalaris Therapeutics, Inc. (Issuer) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)